Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	233.67	182.95	17.45	25.82	57.03	-
Revenue Growth (YoY)	449.03%	948.62%	-32.42%	-54.73%	-	-
Cost of Revenue	72.11	66.21	51.91	43.58	43.79	18.83
Gross Profit	161.56	116.74	-34.46	-17.76	13.24	-18.83
Selling, General & Admin	270.73	237.31	108.7	44.95	25.4	8.17
Operating Expenses	270.73	237.31	108.7	44.95	25.4	8.17
Operating Income	-109.17	-120.57	-143.16	-62.71	-12.16	-27
Interest Expense	-9.08	-7.85	-3.35	-2.2	-	-
Interest & Investment Income	15.35	15.01	10.34	3.5	0.04	0.19
Other Non Operating Income (Expenses)	-0.34	0.59	-0.1	0.09	-0	-
EBT Excluding Unusual Items	-103.23	-112.82	-136.27	-61.33	-12.12	-26.81
Gain (Loss) on Sale of Investments	0.23	-0.79	0.38	-0.77	-1.58	-
Gain (Loss) on Sale of Assets	-	-	-	-	-0.07	-
Other Unusual Items	-1.94	-1.94	-	-	-	-
Pretax Income	-104.94	-115.55	-135.89	-62.1	-13.77	-26.81
Income Tax Expense	-	-	-	-0	0.06	0
Net Income	-104.94	-115.55	-135.89	-62.09	-13.83	-26.81
Net Income to Common	-104.94	-115.55	-135.89	-62.09	-13.83	-26.81
Shares Outstanding (Basic)	39	38	29	25	21	6
Shares Outstanding (Diluted)	39	38	29	25	21	6
Shares Change (YoY)	22.50%	27.98%	19.35%	19.78%	231.12%	162.72%
EPS (Basic)	-2.72	-3.07	-4.62	-2.52	-0.67	-4.32
EPS (Diluted)	-2.72	-3.07	-4.62	-2.52	-0.67	-4.32
Free Cash Flow	-67.87	-84.59	-119	-49.54	3.16	-21.59
Free Cash Flow Per Share	-1.76	-2.25	-4.05	-2.01	0.15	-3.48
Gross Margin	69.14%	63.81%	-197.50%	-68.81%	23.22%	-
Operating Margin	-46.72%	-65.90%	-820.53%	-242.92%	-21.32%	-
Profit Margin	-44.91%	-63.16%	-778.89%	-240.51%	-24.25%	-
Free Cash Flow Margin	-29.05%	-46.24%	-682.04%	-191.88%	5.54%	-
EBITDA	-107.75	-119.34	-142.28	-62.39	-11.85	-26.9
EBITDA Margin	-46.11%	-65.23%	-	-241.66%	-20.77%	-
D&A For EBITDA	1.42	1.23	0.88	0.33	0.31	0.1
EBIT	-109.17	-120.57	-143.16	-62.71	-12.16	-27
EBIT Margin	-46.72%	-65.90%	-	-242.92%	-21.32%	-
Revenue as Reported	233.67	182.95	17.45	25.82	57.03	-

Updated May 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q